Variants within the *MMP3* gene and patellar tendon properties

*in vivo in an asymptomatic population*

**Name and mailing address of corresponding author**

Dr Brandon Paul Foster

Maternal & Fetal Health Research Group

Institute of Human Development

University of Manchester

5th Floor, St. Mary’s Hospital

Oxford Road

M13 9WL

Email address: brandon.foster-2@manchester.ac.uk

**Co-authors**

Dr. Christopher I. Morse¹, Dr. Gladys L. Onambele¹, Dr. Alun G Williams¹,²

¹Institute for Performance Research

Manchester Metropolitan University

Crewe

CW1 5DU

UK

²Institute of Sport, Exercise and Health

University College London
Keywords and phrases

Genetic association studies ▪ MMP3 gene variants ▪ Patellar tendon properties ▪

Asymptomatic ▪ In vivo

Abbreviations:

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Achilles tendinopathies</td>
</tr>
<tr>
<td>BF</td>
<td>Biceps femoris</td>
</tr>
<tr>
<td>CcT</td>
<td>Co-contraction torque</td>
</tr>
<tr>
<td>COL5A1</td>
<td>Gene encoding collagen type V alpha 1 chain</td>
</tr>
<tr>
<td>CSA</td>
<td>Cross-sectional area</td>
</tr>
<tr>
<td>DEXA</td>
<td>Dual X-ray absorptiometry</td>
</tr>
<tr>
<td>E</td>
<td>Elastic modulus</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminotetraacetic acid</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EMG</td>
<td>Electromyography</td>
</tr>
<tr>
<td>E2</td>
<td>Oestradiol</td>
</tr>
<tr>
<td>F_max</td>
<td>Maximal force</td>
</tr>
<tr>
<td>GPa</td>
<td>GigaPascals</td>
</tr>
<tr>
<td>HWE</td>
<td>Hardy-Weinberg Equilibrium</td>
</tr>
<tr>
<td>K</td>
<td>Stiffness</td>
</tr>
<tr>
<td>MMP3</td>
<td>Gene encoding matrix metalloproteinase-3 protein</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>MVC</td>
<td>Maximal voluntary contraction</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PTL</td>
<td>Patellar tendon length</td>
</tr>
<tr>
<td>PTMA</td>
<td>Patellar tendon moment arm</td>
</tr>
<tr>
<td>RMS</td>
<td>Root mean square</td>
</tr>
<tr>
<td>ROM</td>
<td>Range of motion</td>
</tr>
</tbody>
</table>

Abstract

**Background/Aim** Gene variants encoding for proteins involved in homeostatic processes within tendons may influence its material and mechanical properties in humans. The purpose of this study was to examine the association between three polymorphisms of the *MMP3* gene, (rs679620, rs591058 and rs650108) and patellar tendon dimensional and mechanical properties *in vivo.*
Methods 160 healthy, recreationally-active, Caucasian, men and women, aged 18-39 were recruited. Women were not recruited if they were pregnant or using any form of hormone-based contraception. MMP3 genotype determined using real-time PCR was used to select 84 participants showing greatest genetic differences to complete phenotype measurements. Patellar tendon dimensions (volume) and functional (elastic modulus) properties were assessed in vivo using geometric modelling, isokinetic dynamometry, electromyography and ultrasonography.

Results: No significant associations were evident between the completely linked MMP3 rs591058 and rs679620 gene variants, and closely linked rs650108 gene variant, and either patellar tendon volume (rs679620, P = 0.845; rs650108, P = 0.984) or elastic modulus (rs679620, P = 0.226; rs650108, P = 0.088). Similarly, there were no associations with the Z-score that combined those dimension and functional properties into a composite value (rs679620, P = 0.654; rs650108, P = 0.390). Similarly, no association was evident when comparing individuals with/without the rarer alleles (P > 0.01 in all cases).

Conclusions: Patellar tendon properties do not seem to be influenced by the MMP3 gene variants measured. Although these MMP3 gene variants have previously been associated with the risk of tendon pathology, that association is unlikely to be mediated via underlying tendon dimensional and functional properties.
Introduction

Knowledge of the mechanical properties of musculoskeletal tissues including tendon, can assist in understanding the aetiologies of injury (Ker et al. 1988; Seynnes et al. 2009) as well as physical performance potential (Fletcher et al. 2010; Lichtwark and Barclay 2010; Wilson et al. 1994). The primary parameter describing tendon material and mechanical properties is tendon stiffness, which describes the change in length in relation to the force applied (force-displacement relation). It is dependent on the volume of the tendon and tendon modulus, which describes the relation between tendon stress and strain (McGinnis 2005). Therefore, the mechanical properties of tendon are influenced by the volume of tendon as well as the tissue material properties.

Recently, a genetic component has been associated with tendinopathies, particularly that of the *COL5A1* rs12722 gene variant (Collins and Posthumus 2011). One previous study was able to associate this gene variant with mechanical properties of the muscle fascicles and aponeurosis of the vastus lateralis muscle (Kubo et al. 2013), although another was not when examining the patellar tendon (Foster et al. 2014). Therefore, we do not know that the behaviour of the two structures is necessarily comparable. In addition, gene variants within the *MMP3* gene which encodes for matrix metalloproteinase-3 protein, a key regulatory enzyme of the extracellular matrix (ECM) capable of degrading multiple structural components of the ECM such as the collagens (Matrisian 1990), have also been associated with tendinopathies (Raleigh et al. 2009). Specifically, three gene variants within the *MMP3* gene (rs679620, rs591058, rs650108; see Figure 1) have independently been associated with chronic Achilles tendinopathies. Furthermore, the rs679620 gene variant is non-synonymous in that it causes a change in the amino acid sequence, and consequently an altered protein function.
Even though the above gene variants have not been associated with tendon dimensional and mechanical properties *per se*, it is however important to state that all genes that contain sequence variants shown to be associated with tendon injury to date, encode for proteins that serve essential structural and functional roles within tendon (Collins and Raleigh 2009). Indeed, down-regulated expression levels of MMP3 mRNA and its associated proteins have been found in injured or ruptured tendons compared to non-injured tendon groups (de Mos et al. 2007; Ireland et al. 2001; Jones et al. 2006; Lo et al. 2004; Riley et al. 2002). Therefore, it could be postulated that relatively small changes in MMP3 expression within non-pathological ranges, as a result of the function of these gene variants, could result in interindividual variation in the degree of fibrillar collagen degradation, and ultimately the mechanical properties of tendon.

The aim of this study was therefore to investigate whether the *MMP3* rs679620, rs591058 and rs650108 gene variants influence dimensional and mechanical properties within the patellar tendon, through volume and modulus measures *in vivo*, in an asymptomatic population.

**Method**

*Participants:* From an initial screening phase, 160 healthy and recreationally active Caucasian individuals were recruited (100 males and 60 females). In an effort to increase the ability to detect genotype-phenotype associations, a ‘stress the genotype’ approach was implemented (Montgomery et al. 2002). Eighty-four participants (45 males and 39 females) with a high proportion of homozygosity across the three *MMP3* gene variants completed the tendon phenotype assessments. ((mean, (range), (SD) age 23 (18-39), (4) years, height 173
(153-191), (10) cm, body mass 71.6 (47.4-98.9), (12.4) kg, and BMI 24 (18.75-29.8), (2.8) kg/m$^2$). This ‘stress the genotype’ approach should increase the ability to detect a polymorphic influence on patellar tendon properties.

To minimise confounding factors, potential participants were not recruited if they; were non-Caucasian; were very sedentary or very active (completed less than 2.5 hr/wk or more than 5 hr/wk of moderate exercise (Tucker et al. 2011) as determined by a questionnaire); had any current or recent lower limb injuries in the past year before testing, including tendinopathies of the patellar tendon; were aged under 18 or over 40 years; were diabetic; smoked regularly; were regular users of medication; or had a body mass index (BMI) outside the range 18.5-30 kg/m$^2$. Female volunteers were not recruited if pregnant or using hormone-based contraception. The investigation was approved by the local ethics committee at Manchester Metropolitan University, and all participants gave their written informed consent to participate. The study conformed to the latest revision of the Declaration of Helsinki.

**Measurement of tendon dimensional and mechanical properties**

**Maximal patellar tendon isometric force**

All measurements of torque were carried out on an isokinetic dynamometer (Cybex, Phoenix Healthcare, UK) on the left leg. This instrument has been previously assessed for test-retest reliability for measures of peak torque of the knee extensors (Maffiuletti et al. 2007; McCleary and Andersen 1992). The knee was fixed at 90° flexion (full extension = 0°) and hip angle at 85° (supine position = 0°) and in order to minimise any extraneous movement of the hip joint or the trunk, participants were strapped over the shoulders, pelvis and thighs. Settings of chair height and positioning relative to the dynamometer were adjusted individually. Gravity corrections were then made following the manufacturers’ own
procedure, having adjusted the attachment of the lever arm cuff relative to the length of the participant's shank. Previous work from within our laboratory has utilised similar methods of measurement, finding them to be both valid and reliable (Onambele-Pearson et al. 2010; Onambele et al. 2007). Participants were instructed to perform ramp isometric knee extensions to maximum over a 5-7 s period. Maximal tendon force was calculated as described previously (Equation 1), (Onambele-Pearson and Pearson 2007; Pearson and Onambele 2006)

\[
\text{Equation 1: } F_{\text{Max}} = \frac{(MVC_{\text{KE}} + CcT)}{PTMA}
\]

where $F_{\text{Max}}$ is the maximal patella tendon force, $MVC_{\text{KE}}$ the maximal isometric knee-extensor torque (i.e. the measured torque during testing), $CcT$ the knee flexion torque of the hamstrings during knee extension (antagonist co-contraction torque - see next section for calculation), and $PTMA$ the patellar tendon moment arm (see sections below).

*Estimation of antagonist co-contraction using electromyography*

Electromyographic (EMG) activity was assessed using a pair of self-adhesive Ag-AgCl electrodes (Ambu Neurolime 72000-S/25, Ballerup, Denmark) placed in a bi-polar configuration (Zipp 1982) at a site corresponding to the distal one-third on the long head of the biceps femoris (BF) (representative muscle of the knee flexors). The raw EMG signal was collected at a frequency of 2000 Hz, pre-amplified ($\times$ 2000), band pass filtered between 500 and 10 Hz by the same system that processed the torque data (Acknowledge, Biopac Systems, Santa Barbara, CA, USA), and displayed in real-time on the same output graph (iMac, Apple, California). The root mean square (RMS) EMG activity corresponding to the peak torque period was analysed and averaged for a 500 ms period during the plateau of peak torque (i.e.
250 ms either side of the instantaneous peak torque). These EMG data were used as a measure of antagonist co-contraction (i.e. CcT) during isometric knee extensions (Reeves et al. 2003), calculated as the product of BF EMG activity during MVC\textsubscript{KE}, divided by BF peak flexor EMG at 90° knee flexion MVC, multiplied by hamstrings maximal flexion torque.

*Patellar tendon displacement*

Patellar tendon displacement was determined using real-time B-mode ultrasonography (AU5, Esaote, Biomedica, Italy) as described previously (Onambele et al. 2007). Briefly, during a ramp isometric knee extension performed over 5-7 s with the knee fixed at 90° flexion, the ultrasound probe (7.5 MHz linear array probe, 40 mm wide) was positioned in a sagittal plane over the patellar tendon alternatively over; a) patella proximal (inferior pole of the patella) or b) tibia-distal (tibial tuberosity) excursions, so that the sum of tibial and patellar displacements would be computed as total displacement. Total displacements was determined at 10% PT force level intervals (from 10-100%) using digitising software (Kinovea, version 0.8.15, Joan Charmant & Contributors, France), consistent with others (Onambele et al. 2007). This method is widely used and has high reliability (e.g. (Kubo et al. 2001; Pearson and Onambele 2006; Reeves et al. 2003)). Measurements were taken after five preconditioning knee extension contractions to ensure reproducibility (Maganaris 2003), and in the early afternoon (between 1200h and 1500h), to minimise variability in tendon stiffness related to time of day (Pearson and Onambele 2006).

*Patellar tendon moment arm length*

Patellar tendon moment arm length (PTMA) was measured from an 11 s sagittal plane scan of the left leg of each participant at rest, using a single, low-energy X-ray beam (0.9 μSv) protocol on a DEXA (Dual X-ray Absorptiometry) scan (Hologic QDR, Vertec, Reading,
UK). For the imaging limb, the participant lay on their right-hand side with the left hip and knee flexed at 90° so that the source detector probes could pass across the knee within a 20 cm scanning window. The PTMA was defined as the perpendicular distance from the patellar tendon to the midpoint of the distance between the estimated tibio-femoral contact points in the lateral and medial femoral condyles (Baltzopoulos 1995; Tsaopoulou et al. 2006). The measurement of 2D PTMA using DEXA shows very strong agreement with MRI (Erskine et al. 2014).

Calculation of patellar tendon stiffness
Patellar tendon stiffness ($K, \text{Nmm}^{-1}$), was calculated from the slope of the tangents of the force-displacement relations (at 10% force intervals), which were fitted with a second-order polynomial function forced through zero. The 10% force intervals derive from the average maximum force ($F_{\text{Max}}$) experienced by the tendon during three separate ramp KE MVC (see Equation 1). The displacement of the patella tendon was measured as described previously. In addition, to allow for stiffness comparisons at an absolute load across populations, tendon stiffness was also calculated at a standardised force level which corresponded to just under the maximum baseline value of the weakest person (male=1067 N; female=1034 N).

Calculation of Elastic Modulus
Patellar tendon cross-sectional area (PTCSA) and patellar tendon length (PTL) were measured in the resting state at a knee joint angle of 90°. PTCSA was determined from the mean of transverse-plane ultrasound images taken at 25, 50 and 75% of patellar tendon length, and processed using digitising software (Image J, National Institute of Health, Bethesda, MD, USA). PTL was assessed from sagittal-plane ultrasound images and measured from the inferior pole of the patella to the superior aspect of the tibial tuberosity. Elastic
Modulus (E) in GPa was calculated by multiplying \( K \) by the ratio of PTL to PTCSA (\( E = K \times \frac{PTL}{PTCSA} \)).

**Calculation of tendon volume**

Patellar tendon volume (PTV) was calculated by geometric principles assuming a uniformly tapering truncated cone between measurement positions (i.e. the product of PTCSA at the three sections of the tendon, 25, 50, 75%, and PTL). However, these sections represent the ‘central’ volume so it is possible that the normalisation is over-estimating the stress in the tendon, since not all the tissue is taken into account in the central 50% portion. Muscle and tendon geometry have previously been modelled using similar methods (Fuller et al. 1999; Jones and Pearson 1969; Tothill and Stewart 2002).

**Z-score analyses:** To provide a stable measure of the overall association of genotype with patellar tendon properties, composites were formed with unit-weighted Z-scores of constituent tests (Ackerman and Cianciolo 2000), i.e. Elastic Modulus and tendon volume. Hence, the dimensional (volume) and functional (Elastic Modulus) properties of tendon could be scaled and analysed simultaneously. Thus, the raw test scores of E (GPa) and volume (mm\(^3\)) were converted to Z-scores using Equation 2;

\[
\text{Equation 2: } Z\text{-score} = \frac{\text{variable score} - \text{mean}}{\text{standard deviation}}
\]

\[
Z\text{-score}_{\text{Composite}} = Z\text{-score}_E + Z\text{-score}_{\text{PTV}}
\]
Genetic analysis

Sample collection

Buccal cells were collected using mouth swabs (Whatman Sterile OmniSwab, GE Healthcare, USA). Samples were immediately stored at -20°C until DNA extraction.

DNA extraction

Standard procedures for genomic DNA isolation from buccal swabs were carried out using the Qiagen QIAcube spin column protocol and buffers in the Qiagen DNA Blood Mini kit (Qiagen, West Sussex, UK).

DNA Quantification

The concentration and purity of the sample was calculated using a biophotometer (WPA UV1101, Biochrom, Cambridge, UK). Briefly, 12 µL of the DNA sample was pipetted into a glass cuvette, the absorbance readings of ultra-violet light at wavelengths of 260 nm and 280 nm were performed and the 260/280 nm ratio was determined. Good quality DNA will have a ratio of 1.7-2.0 (Glasel 1995), and all samples fell within these ratios. Eluted DNA concentrations were in the region of 10-30 ng/µL.

MMP3 genotyping

MMP3 rs679620, rs591058 and rs650108 genotypes were determined using fluorescence-based TaqMan real-time polymerase chain reaction (PCR). Predesigned primers and allele-specific probes specific to the ‘G’ allele (VIC) and ‘A’ allele (FAM) of the MMP3 rs679620 gene variant, ‘C’ allele (VIC) and ‘T’ allele (FAM) of the MMP3 rs591058 gene variant, and ‘A’ allele (VIC) and ‘G’ (FAM) of the MMP3 rs650108 gene variant, were used (Applied Biosystems, Foster City, CA, USA). The assay volume within each well of a 96-well PCR
plate (Bio-Rad Laboratories Ltd, Herts, UK) was 10 µL, which included 1 µL of purified DNA, 5 µL of 2 X TaqMan genotyping master mix (Applied Biosystems), 0.5 µL of 20X genotyping assay (Applied Biosystems) and 3.5 µL nuclease-free H₂O (Qiagen). Each PCR run included positive controls for each genotype and negative controls (sterile distilled water). The PCR plate was sealed using MicroSeal ‘B’ Adhesive seals (Bio-Rad) and ran on a Chromo4 Real-Time PCR Detection System (Bio-Rad) for 10 min at 95°C. This was followed by 40 cycles of denaturing at 92°C for 15 s, primer annealing and extension at 60°C for 60 s, and plate read. Genotypes were determined by endpoint fluorescence of VIC and FAM signals using the Chromo4 PCR machine, and results were analysed using Opticon Monitor Software version 3.1.32 (Bio-Rad). All analyses were run in duplicate, there was 100% agreement between duplicate wells and genotyping was completed in all samples.

Hardy-Weinberg Equilibrium

Genotype data were tested for Hardy-Weinberg Equilibrium (HWE) using a freely available software package (Rodriguez et al. 2009). This test was conducted on the initial cohort before selecting individuals for the phenotype tests (based on a higher degree of homozygosity), in order to establish whether the genotype and allele frequencies were constant between the initial cohort and the general population. Indeed, the genotype data for this cohort was in HWE ($P > 0.05$ with 1df (one degree of freedom)).

Oestriadiol measures

It has been reported that oestradiol levels are associated with tendon mechanical properties in vivo (Burgess et al. 2009). Therefore, following the measures of patellar tendon properties, female participants reported to the biochemistry laboratory where whole blood (5 mL) was drawn from a superficial forearm vein into serum separator tubes containing anti-coagulant
(EDTA) (Sarstedt Monovette-Red cap, Numbrecht, Germany). After storage on ice for ~30 minutes, the blood was centrifuged at 2-5°C for 10 min at 4100 rpm, with the supernatant extracted (~2 mL) and stored at -20°C for later analysis. Serum 17ß-oestradiol (E2) was quantitatively determined using standard enzyme-linked immunosorbent assay (ELISA) procedures (Alpha Diagnostic International, San Antonio, USA; minimal detectable concentration of ~10 pg/mL, intra-assay precision of 9.9%, inter-assay precision of 10.1%). E2 concentration at day 1 of the menstrual cycle was extrapolated using data from women with similar characteristics to those in the current study (i.e. age range 20-36 years, no use of contraceptives) (Stricker et al. 2006). Extrapolated serum oestradiol in the 39 female participants was therefore 34.0 (30.0) pg/mL.

**Statistical power to detect genotype-phenotype associations**

Statistical power calculations were performed using G*Power 3.1.6 software (Franz Faul, Universitat Kiel, Germany) (Faul et al. 2007). With alpha set at 0.05 and beta at 0.80, using mean and standard deviation data of patellar tendon properties obtained in our lab, it was estimated that approximately 80 participants would be required to detect differences in the order of ~1-2% for tendon volume and ~10-15% for tendon modulus between two genotype groups. Two genotype groups were used in this calculation because the intention, *a priori*, was to ‘stress the genotype’ (see first paragraph of Method) by conducting detailed phenotype testing on individuals homozygous for the polymorphisms under study where possible, while combining any small number of heterozygotes with one homozygote group. This was largely successful for rs591058 and rs679620 (cf. top row of Table 1 in Results) but less successful for rs650108 (cf. top row of Table 2) where statistical power therefore did not reach the target value.
Statistical analyses

Reliability of patellar tendon CSA, length, maximal displacement, and maximal strain were evaluated using ratio limits of agreement (Nevill and Atkinson 1997) to quantify the absolute reliability or ‘agreement’ between measurements on separate occasions. All data were analysed with SPSS version 19.0.0. One-way analysis of variance (ANOVA) was performed on all three genotype groups and the measures of PTV and Z-scores. In addition, independent t-tests were performed on volume and Z-scores when combining heterozygotes with the smallest homozygote group. The Kruskal-Wallis non-parametric equivalent statistical test was performed on E and its association with the three genotype groups, while the Mann-Whitney U test was used to compare E between one homozygote group and the other combined genotype group. PTV differed between sexes and BMI was correlated with both PTV and Z-score, so sex and BMI were used as covariates accordingly. Age and oestradiol concentration showed no correlations with any phenotype so were not used as covariates. Alpha was set at 0.05. Unless otherwise stated, data are presented as mean (standard deviation).
Figure 1 A simplified representation of the *MMP3* gene in the negative orientation on chromosome 11. Both exons (black rectangles) and introns (horizontal lines) are shown, with exons being indicated by numbers. Untranslated regions (solid white rectangles) are also shown. All three gene variants are separated by similar distances; rs679620 in exon 2 is 2282 base pairs from rs5901058 in intron 4, whereas rs591058 is 2551 base pairs from rs650108 in intron 8. This figure is modified from Raleigh et al. (2009) with information on minor allele frequency and loci derived from Ensembl (http://www.ensembl.org/index.html)

Results

There were no significant differences in age, height, mass and BMI between the three genotype groups, nor between the combined genotype groups of the *MMP3* rs591058/679620 gene variants (Table 1) and *MMP3* rs650108 gene variant (Table 2). The *MMP3* rs591058 and rs679620 gene variants produced identical results and are therefore presented simultaneously, because they were in perfect linkage disequilibrium (LD) (allele C of rs591058 corresponded to allele G of rs679620).
Between-day repeated measurements of tendon CSA, length, maximal displacement, and maximal strain in a subgroup of participants were examined using ratio limits of agreement. Tendon volume showed no bias and excellent agreement ($\times/\div 1.019$) and E showed no bias and very good agreement ($\times/\div 1.144$).

As circulating oestradiol levels showed no significant correlation with patellar tendon properties (CSA, $r = 0.155$, $P = 0.345$; Tendon length, $r = -0.243$, $P = 0.137$; Maximal displacement, $r = -0.258$, $P = 0.113$; Maximal strain, $r = -0.171$, $P = 0.298$; Maximal stiffness, $r = 0.148$, $P = 0.368$; Standardised stiffness, $r = 0.267$, $P = 0.100$; Volume, $r = 0.010$, $P = 0.950$; E, $r = 0.146$, $P = 0.375$; Z-scores, $r = 0.055$, $P = 0.740$), and having adjusted for non-genetic factors such as sex and BMI, male and female participants data were therefore pooled into a single population. There were no significant differences in patellar tendon CSA, length, maximal displacement, maximal strain, stiffness at a common force level (Online Resource 1), or indeed tendon volume ($P = 0.845$) and E ($P = 0.226$) or Z-scores ($P = 0.654$) (Figure 2), between the three genotype groups of the MMP3 rs591058/679620 gene variants. Nor, were there any significant differences when comparing the TT/AA genotype groups to the combined CT and CC/GA and GG genotype groups (Volume, $P = 0.859$; E, $P = 0.125$; Z-scores, $P = 0.357$). Both the CT and CC/GA and GG genotype groups were combined due to the small CC and GG groups of the rs590158 and rs679620 gene variants, respectively.

In addition, there were no significant differences between the three genotype groups of the MMP3 rs650108 gene variant in patellar tendon CSA, length, maximal displacement, maximal strain, and stiffness (Online Resource 2), or for measures of volume ($P = 0.984$), E
(\(P = 0.088\)) or Z-scores (\(P = 0.390\)) (Figure 3). Or indeed, when comparing the GG genotype group to the combined GA and AA genotype groups (Volume, \(P = 0.881\); E, \(P = 0.112\); Z-scores, \(P = 0.483\)). The GA and AA genotype groups were combined due to the small AA group size.

Table 1 Age, physical characteristics and genotype at \(MMP3\) rs591058 and rs679620 loci. P-values for the comparisons of three genotype groups, and two genotype groups (when heterozygotes were pooled with one homozygote) were derived from a one-way ANOVA, and independent t-test, respectively.

<table>
<thead>
<tr>
<th></th>
<th>All</th>
<th>CC</th>
<th>CT</th>
<th>TT</th>
<th>P-value (3 group comparison)</th>
<th>CC &amp; CT GG &amp; GA</th>
<th>P-value (2 group comparison)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>84</td>
<td>29</td>
<td>6</td>
<td>49</td>
<td>-</td>
<td>35</td>
<td>-</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>22.7 (4.0)</td>
<td>21.5 (2.3)</td>
<td>21.7 (0.8)</td>
<td>23.5 (4.8)</td>
<td>0.247</td>
<td>21.5 (2.2)</td>
<td>0.120</td>
</tr>
<tr>
<td>Sex (% male)</td>
<td>53.6</td>
<td>41.4</td>
<td>0</td>
<td>67.4</td>
<td>-</td>
<td>34.3</td>
<td>-</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>172.7 (9.5)</td>
<td>171.9 (10.4)</td>
<td>167.8 (6.2)</td>
<td>173.7 (9.2)</td>
<td>0.196</td>
<td>171.2 (9.9)</td>
<td>0.179</td>
</tr>
<tr>
<td>Mass (kg)</td>
<td>71.6 (12.4)</td>
<td>70.5 (12.9)</td>
<td>62.7 (9.4)</td>
<td>73.3 (12.0)</td>
<td>0.114</td>
<td>69.2 (12.6)</td>
<td>0.129</td>
</tr>
<tr>
<td>BMI (kg m(^{-2}))</td>
<td>24.0 (2.8)</td>
<td>24.1 (3.1)</td>
<td>24.7 (3.3)</td>
<td>23.8 (2.5)</td>
<td>0.690</td>
<td>24.2 (3.1)</td>
<td>0.477</td>
</tr>
</tbody>
</table>
Table 2 Age, physical characteristics and genotype at the *MMP3* rs650108 loci. The P-values of the GG vs GA vs AA, and GG vs GA/GG combined genotype groups are derived from a one-way ANOVA, and independent t-test, respectively.

<table>
<thead>
<tr>
<th></th>
<th>All</th>
<th>GG</th>
<th>GA</th>
<th>AA</th>
<th>(P)-value (3 group comparison)</th>
<th>GA &amp; AA</th>
<th>(P)-value (2 group comparison)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n</strong></td>
<td>84</td>
<td>61</td>
<td>15</td>
<td>8</td>
<td>-</td>
<td>23</td>
<td>-</td>
</tr>
<tr>
<td><strong>Age (yr)</strong></td>
<td>22.7 (4.0)</td>
<td>23.0 (4.5)</td>
<td>21.1 (2.3)</td>
<td>23.0 (2.5)</td>
<td><strong>0.143</strong></td>
<td>21.7 (2.5)</td>
<td>0.404</td>
</tr>
<tr>
<td><strong>Sex (% male)</strong></td>
<td>53.6</td>
<td>62.3</td>
<td>23.1</td>
<td>50</td>
<td>-</td>
<td>34.3</td>
<td>-</td>
</tr>
<tr>
<td><strong>Height (cm)</strong></td>
<td>172.7 (9.5)</td>
<td>173.5 (9.4)</td>
<td>169.4 (10.1)</td>
<td>172.7 (8.7)</td>
<td><strong>0.340</strong></td>
<td>170.6 (9.6)</td>
<td>0.216</td>
</tr>
<tr>
<td><strong>Mass (kg)</strong></td>
<td>71.6 (12.4)</td>
<td>72.9 (12.5)</td>
<td>66.8 (12.2)</td>
<td>70.6 (10.4)</td>
<td><strong>0.218</strong></td>
<td>68.1 (11.5)</td>
<td>0.111</td>
</tr>
<tr>
<td><strong>BMI (kg.m(^{-2}))</strong></td>
<td>24.0 (2.8)</td>
<td>24.1 (2.6)</td>
<td>23.2 (2.8)</td>
<td>24.7 (3.8)</td>
<td><strong>0.408</strong></td>
<td>23.7 (3.2)</td>
<td>0.628</td>
</tr>
</tbody>
</table>
Discussion

This study finds no association between the three variants of the \textit{MMP3} gene investigated, and patellar tendon properties. Specifically, the \textit{MMP3} gene variants investigated do not associate with dimensional (volume) and functional (E) properties of the patellar tendon, or indeed as a composite (Z-scores), in an asymptomatic population. In this study, patellar tendon modulus was comparable with other data for this phenotype in healthy, young, male and female combined subpopulations, between 0.44-0.72 GPa compared with 0.5-0.6 GPa (O'Brien et al. 2010) and 0.75 GPa (Hsin-Yi and Paul 2010). The larger sample size used in the present study (\(n = 84\)) compared to those aforementioned studies (\(n = 10-20\)) (Hsin-Yi and Paul 2010; O'Brien et al. 2010) gives us increasing confidence that the modulus data are representative of the wider population. No previous study has reported PTV.

Although none of the variants investigated in this study were found to be associated with patellar tendon properties, it does not exclude the possibility that other variants within genes clustered in close proximity to the \textit{MMP3} gene on chromosome 11q22, such as \textit{MMP10}, \textit{MMP1}, and \textit{MMP12}, are associated with patellar tendon properties. Like \textit{MMP3}, the protein products of these genes are capable of degrading a diverse array of extracellular matrix (ECM) proteins (Pasternak and Aspenberg 2009; Somerville et al. 2003), so one might assume that because \textit{MMP3} variants have been associated with tendinopathies (Raleigh et al. 2009), associations may be observed between these other \textit{MMP} gene variants and tendon properties because the intrinsic regulatory proteins associated with tendon pathologies are also directly involved in non-pathological maintenance processes within tendon.
Consistency of results when considering each of the three gene variants and measures of patellar tendon properties was expected, given that they are known to be in high linkage disequilibrium with one another. In particular, the rs591058 and rs679620 variants are in perfect linkage disequilibrium, with the ‘C’ allele of rs591058 corresponding with the ‘G’ allele of rs679620. In addition, the rs650108 variant displays high linkage disequilibrium with the rs679620 and rs591058 variants ($r = 0.673$, $P = 0.01$).

A promoter polymorphism within the $MMP3$ gene (rs3025058) is also believed to be tightly linked to the rs679620 variant (Beyzade et al. 2003; Chen et al. 2012; Raleigh et al. 2009). Both markers are associated with MMP3 expression levels, notably the rs3025058 5A allele and the rs679620 ‘A’ allele are associated with relatively lower levels of MMP3, and the highest level of pathological activity related to rheumatoid arthritis. In addition, lower MMP3 protein expression levels have been reported in human tendon displaying pathological characteristics (de Mos et al. 2007; Ireland et al. 2001; Jones et al. 2006; Parkinson et al. 2010; Riley et al. 2002). These observations may represent a failure of the normal matrix remodelling process (Riley et al. 2002). However within a non-pathological range, lower MMP3 levels may favour a state of imbalance with greater synthesis relative to degradation, thus, substrates involved in cross-linking and stabilisation of intact fibrillar collagen may be relatively less affected by degradation processes.

Ultimately, the AA genotype of the rs679620 variant may associate with a higher matrix stiffness and higher $E$, when considering the above rationale, yet this assumption was not evident in this study as $E$ was not significantly different between the AA and GG genotype groups ($P = 0.226$; 0.44 GPa vs. 0.48 GPa, respectively). Nor, was it evident in the only other previous genetic association study attempting to link this gene variant with tendon
Correspondingly, the TT and CC genotype groups of the rs591058 variant do not differ significantly. However, the functional significance of the rs650108 variant has yet to be determined, most likely due to the fact that it resides in an intron, which makes it more difficult to explain why as part of a haplotype, it associates with pathological states (Koch et al. 2010; Raleigh et al. 2009). It may be that within normal physiological ranges, the activity of MMP3 is tightly controlled by tissue inhibitors of MMPs (TIMPs) (Riley 2005), thus inhibiting the degeneration of the ECM and loss of material properties. This has been reported in stress-deprived tendons in vitro, subjected to inhibitors to prevent the activation of MMP activity (Arnoczky et al. 2007). Therefore, variations in MMP3 activity related to differences in the ability to turn over the matrix may only become apparent following damage and the onset of pathological states.

We believe a valuable approach undertaken in this study was to increase the ability to detect genotype-phenotype associations. By recruiting a high proportion of participants from an original cohort who were homozygous for the gene variants under investigation, we were able to target our efforts during a detailed phenotype assessment. Hence, the genotype was being ‘stressed’ (Montgomery et al. 2002). Despite this approach, we observed no associations, although it is precisely because of our approach that we have confidence in our conclusions. Future researchers investigating gene variants and their association with tendon properties are encouraged to adopt this approach in synergy with a larger sample size where possible (a limitation of this study), to further increase the ability to detect associations of small effect size and provide even greater confidence in findings. Arguably, using a large sample size becomes even more important when considering that whole tendon mechanical properties are likely to be a product of the structure and function, and thus mechanical properties, of the mechanical stiffness of the knee extensors and plantar flexors (Kubo et al. 2013).
ECM at a sub-structural level, i.e. the inter-fascicular matrix. Furthermore, a recent study’s findings *in vivo* (Pearson et al. 2014) suggests that there may be regional strain differences between the deep, middle, and surface structures at the proximal and distal aspects of the patellar tendon, exacerbating the difficulties of associating gene variants with whole tendon properties.

Future research should also attempt to determine whether there is a differential expression of *MMP3* genes in tendon displaying relatively high and low tendon modulus, to assist in determining whether these genes are causally implicated in modifying mechanical properties of tendon, through mechanisms which remodel its microstructure. Additionally, associations could be established between protein expression levels and the genotypes of *MMP3* sequence variants.

In conclusion, this study finds no evidence of an association between the three variants of the *MMP3* gene investigated and dimensional and mechanical properties of the patellar tendon. However, our observations need replication and/or new study using other tendons. In addition, the relationship between pathological tendon conditions and tendon mechanical properties should be investigated to improve injury prevention models.

**Footnotes**
Competing interests: None

Ethics approval: Ethics approval was provided by Human Research Ethics Committee: of Manchester Metropolitan University

Patient consent: Obtained


10.1177/0363546506296043


10.1038/gene.2011.46


10.1159/000235701


10.1016/j.atherosclerosis.2009.08.021
7NYABQKW7WX4T720 [pii]


10.1016/j.jbiomech.2006.04.001


2002.035576 [pii]


10.111/j.1600-0838.2005.00456.x


10.1093/aje/kwn359

Figure 2 Patellar tendon properties for \textit{MMP3} rs591058 and rs679620 genotype groups.

Elastic modulus and Z-scores are expressed as median (range).
Figure 3 Patellar tendon properties for *MMP3* rs650108 genotype groups. Elastic modulus and Z-scores are expressed as median (range).